AbbVie
ABBV
£128.71
Share price
1.12%
Change (1 day)
-5.12%
Change (1 year)
Categories
The biotechnology and pharmaceutical company Abbvie, spelled AbbVie, was founded in 2013 as a spin-off from Abbott Laboratories and is traded on the NYSE stock exchange in the S&P 100 index under the symbol “ABBV”.
Revenue for AbbVie (ABBV)
Revenue in 2024 (TTM): £44.01 Billion
According to AbbVie's latest financial reports the company's current revenue (TTM 
) is £42.13 Billion. an increase over the revenue in the year 2023 that were of £42.63 Billion. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for AbbVie from 2011 to 2024
Annual revenue
| Year | Revenue | Change |
|---|---|---|
| 2024 | £44.89 B | 5.29% |
| 2023 | £42.63 B | -11.15% |
| 2022 | £47.98 B | 15.26% |
| 2021 | £41.63 B | 23.89% |
| 2020 | £33.60 B | 32.46% |
| 2019 | £25.36 B | -1.68% |
| 2018 | £25.80 B | 23.59% |
| 2017 | £20.87 B | 0.48% |
| 2016 | £20.77 B | 34.7% |
| 2015 | £15.42 B | 20.32% |
| 2014 | £12.82 B | 12.55% |
| 2013 | £11.39 B | 0.17% |
| 2012 | £11.37 B | 1.32% |
| 2011 | £11.22 B |
Revenue for similar companies or competitors
| Company | Revenue | Revenue differencediff. | Country |
|---|---|---|---|
 | £47.59 B | 12.94% | 🇺🇸 USA |
 | £36.12 B | -14.26% | 🇺🇸 USA |
 | £33.69 B | -20.04% | 🇺🇸 USA |
 | £25.00 B | -40.67% | 🇺🇸 USA |
 | £21.50 B | -48.96% | 🇺🇸 USA |
 | £7.23 B | -82.82% | 🇺🇸 USA |
 | £30.05 B | -28.67% | 🇬🇧 UK |
 | £40.44 B | -4.01% | 🇬🇧 UK |
 | £1.76 B | -95.82% | 🇺🇸 USA |